FDA Approves PROLATE — Forte Bio-Pharma LLC
Forte Bio-Pharma LLC announced the approval of Prolate (oxycodone hydrochloride and acetaminophen), expanding its product portfolio as a cost-effective generic option and increasing competitive pressure on branded pain management therapies in the market.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed